Vancomycin’s Red Flag: A Review of Red Man Syndrome

Abstract

Vancomycin-induced Red Man Syndrome (RMS) is a common adverse drug reaction characterized by non-IgE mediated histamine release, resulting from the rapid intravenous infusion of vancomycin. Unlike a true allergic reaction, RMS is a direct pharmacological effect that can cause significant patient discomfort and lead to unnecessary treatment interruptions. The clinical presentation typically includes flushing and erythema of the face, neck, and upper torso, along with pruritus, urticaria, and, in more severe cases, angioedema and hypotension. The primary management strategy involves immediately stopping the infusion and administering antihistamines. Prevention is paramount, with the most effective measures being slowing the infusion rate to a minimum of 60 minutes per gram and, for high-risk patients, premedication with H1 and H2 blockers. Understanding the distinct mechanism and implementing proper preventive protocols are crucial for healthcare professionals to ensure the safe and effective administration of vancomycin.